Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

PURPOSE: The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer (AGC). However, as demonstrated in HER2-negative AGC, oxaliplatin-based regimens could improve tolerance remaining effective. The aim of this t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Chemother Pharmacol
Auteurs principaux: Rivera, Fernando, Romero, C., Jimenez-Fonseca, P., Izquierdo-Manuel, M., Salud, A., Martínez, E., Jorge, M., Arrazubi, V., Méndez, J. C., García-Alfonso, P., Reboredo, M., Barriuso, J., Muñoz-Unceta, N., Jimeno, R., López, C.
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2019
Sujets:
Clinical Trial Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6779679/
https://ncbi.nlm.nih.gov/pubmed/30927036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03820-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires